Anti-HLA-DQ antibodies are highly and independently related to the C1q-binding capacity of HLA antibodies.

[1]  J. Alberú,et al.  C1Q Assay Results in Complement-Dependent Cytotoxicity Crossmatch Negative Renal Transplant Candidates with Donor-Specific Antibodies: High Specificity but Low Sensitivity When Predicting Flow Crossmatch , 2016, Journal of transplantation.

[2]  G. Russ,et al.  HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[3]  S. A. Vallipakorn,et al.  Role of Pretransplant Complement-fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation. , 2016, Transplantation proceedings.

[4]  J. Friedewald,et al.  Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  D. Kaufman,et al.  C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection , 2015, Transplantation.

[6]  P. Nickerson,et al.  Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. , 2015, Journal of the American Society of Nephrology : JASN.

[7]  J. Scoazec,et al.  Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. , 2015, Journal of the American Society of Nephrology : JASN.

[8]  M. Roustit,et al.  Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor‐specific antibodies , 2014, Transplant international : official journal of the European Society for Organ Transplantation.

[9]  J. Pascual,et al.  Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? , 2013, Transplant immunology.

[10]  X. Jouven,et al.  Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.

[11]  V. Acuña-Alonzo,et al.  HLA Class I and Class II Conserved Extended Haplotypes and Their Fragments or Blocks in Mexicans: Implications for the Study of Genetic Diversity in Admixed Populations , 2013, PloS one.

[12]  J. Alberú,et al.  Probability of deceased donor kidney transplantation based on % PRA. , 2013, Transplant immunology.

[13]  L. Ratner,et al.  Donor-specific antibodies adversely affect kidney allograft outcomes. , 2012, Journal of the American Society of Nephrology : JASN.

[14]  W. Suki,et al.  Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. , 2012, Kidney international.

[15]  C. Roufosse,et al.  De Novo DQ Donor-Specific Antibodies Are Associated With a Significant Risk of Antibody-Mediated Rejection and Transplant Glomerulopathy , 2012, Transplantation.

[16]  M. Verhaar,et al.  Pretransplant Donor‐Specific HLA Class‐I and ‐II Antibodies Are Associated With an Increased Risk for Kidney Graft Failure , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  S. Sutherland,et al.  Complement‐fixing donor‐specific antibodies identified by a novel C1q assay are associated with allograft loss , 2012, Pediatric transplantation.

[18]  D. Tyan,et al.  Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. , 2011, Human immunology.

[19]  A. Lu,et al.  Desensitization protocols and their outcome. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[20]  S. Busque,et al.  C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney Transplantation , 2011, Transplantation.

[21]  Dominique Charron,et al.  Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. , 2010, Journal of the American Society of Nephrology : JASN.

[22]  P. Terasaki,et al.  “Natural” Human Leukocyte Antigen Antibodies Found in Nonalloimmunized Healthy Males , 2008, Transplantation.

[23]  D. Nochy,et al.  Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. , 2008, Contributions to nephrology.

[24]  A. Zeevi,et al.  Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes. , 2008, Transplant immunology.

[25]  A. Wiseman,et al.  Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  M. Pescovitz,et al.  Presensitization: the problem and its management. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[27]  Junchao Cai,et al.  Humoral theory of transplantation: further evidence. , 2005, Current opinion in immunology.

[28]  G. Böhmig,et al.  [C4d]FlowPRA screening--a specific assay for selective detection of complement-activating anti-HLA alloantibodies. , 2005, Human immunology.

[29]  P. Terasaki,et al.  Flow cytometric detection of HLA antibodies using a spectrum of microbeads. , 1999, Human immunology.

[30]  P. Terasaki,et al.  Significance of the positive crossmatch test in kidney transplantation. , 1969, The New England journal of medicine.

[31]  J. Lunz,et al.  Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[32]  C. Haisch,et al.  Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. , 2006, Clinical transplants.

[33]  N. Lachmann,et al.  Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up. , 2006, Clinical transplants.